See more : Tata Steel Limited (TTST.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Zhongchao Inc. (ZCMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhongchao Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Dollar Industries Limited (DOLLAR.BO) Income Statement Analysis – Financial Results
- CARsgen Therapeutics Holdings Limited (2171.HK) Income Statement Analysis – Financial Results
- Liminal BioSciences Inc. (LMNL) Income Statement Analysis – Financial Results
- Blue Ridge Real Estate Company (BRRE) Income Statement Analysis – Financial Results
- Dorsel Holdings Ltd (DRSH.TA) Income Statement Analysis – Financial Results
Zhongchao Inc. (ZCMD)
About Zhongchao Inc.
Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 19.43M | 14.15M | 16.30M | 17.99M | 14.88M | 12.87M | 9.82M |
| Cost of Revenue | 10.92M | 7.79M | 6.86M | 6.12M | 4.66M | 4.46M | 3.97M |
| Gross Profit | 8.51M | 6.36M | 9.44M | 11.87M | 10.23M | 8.41M | 5.85M |
| Gross Profit Ratio | 43.80% | 44.92% | 57.92% | 65.99% | 68.72% | 65.36% | 59.56% |
| Research & Development | 514.41K | 411.52K | 758.88K | 816.55K | 864.32K | 1.45M | 943.25K |
| General & Administrative | 6.70M | 6.80M | 5.86M | 3.12M | 2.52M | 1.43M | 1.14M |
| Selling & Marketing | 6.71M | 2.10M | 3.14M | 3.44M | 3.20M | 2.26M | 2.72M |
| SG&A | 13.41M | 8.90M | 9.00M | 6.57M | 5.72M | 3.69M | 3.85M |
| Other Expenses | 7.87M | 262.44K | 34.00K | 305.57K | 534.02K | 37.36K | 275.02K |
| Operating Expenses | 21.80M | 9.31M | 9.76M | 7.38M | 6.58M | 5.13M | 4.80M |
| Cost & Expenses | 32.72M | 17.11M | 16.62M | 13.50M | 11.24M | 9.59M | 8.77M |
| Interest Income | 237.05K | 142.01K | 175.99K | 146.97K | 211.48K | 191.61K | 17.33K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 923.61K | 730.31K | 679.79K | 403.01K | 240.51K | 28.78K | 16.27K |
| EBITDA | -4.90M | -2.22M | 382.24K | 4.49M | 3.64M | 3.30M | 1.06M |
| EBITDA Ratio | -25.23% | -15.72% | 2.35% | 27.32% | 26.23% | 25.75% | 10.85% |
| Operating Income | -13.28M | -2.95M | -320.74K | 4.49M | 3.64M | 3.27M | 1.05M |
| Operating Income Ratio | -68.35% | -20.88% | -1.97% | 24.96% | 24.47% | 25.45% | 10.68% |
| Total Other Income/Expenses | 1.31M | 404.46K | 209.99K | 452.53K | 745.50K | 228.97K | 292.35K |
| Income Before Tax | -11.98M | -2.55M | -110.75K | 4.94M | 4.39M | 3.50M | 1.34M |
| Income Before Tax Ratio | -61.63% | -18.02% | -0.68% | 27.47% | 29.48% | 27.23% | 13.66% |
| Income Tax Expense | -669.76K | 272.31K | -349.42K | 484.79K | 387.14K | 502.13K | -153.95K |
| Net Income | -11.34M | -2.82M | 238.67K | 4.46M | 4.05M | 3.02M | 1.53M |
| Net Income Ratio | -58.33% | -19.94% | 1.46% | 24.78% | 27.19% | 23.47% | 15.58% |
| EPS | -4.35 | -1.09 | 0.10 | 1.83 | 1.87 | 1.45 | 0.78 |
| EPS Diluted | -4.35 | -1.09 | 0.10 | 1.83 | 1.87 | 1.45 | 0.78 |
| Weighted Avg Shares Out | 2.60M | 2.60M | 2.49M | 2.44M | 2.16M | 2.08M | 1.96M |
| Weighted Avg Shares Out (Dil) | 2.60M | 2.60M | 2.49M | 2.44M | 2.16M | 2.08M | 1.96M |
Zhongchao Inc. Announces the On-Going One-Year Leukemia Education Project with Bethune Foundation and BeiGene Shanghai
Zhongchao Inc. Launched New Line of Business Focusing on Tumor and Rare Disease Patient Management
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
Top Penny Stocks News Today: TNXP, ONTX, AREC, LPCN and ZCMD
ZCMD Stock: Why Chinese Healthcare Play Zhongchao Is Skyrocketing Today
ZCMD Stock Price Increases Over 15% Pre-Market: Why It Happened
Zhongchao Renews Contract with China Association of Health Promotion and Education and GlaxoSmithKline
Zhongchao Inc. Promotes Standardized Liver Cancer Diagnosis and Treatment with Medical Associations and Experts
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zhongchao Inc. and Encourages Investors with Losses to Contact the Firm
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zhongchao Inc. and Encourages Investors with Losses to Contact the Firm
Source: https://incomestatements.info
Category: Stock Reports